Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.47 |
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.47 |
| ▸ | CPA1 | P15085 | 3/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5980987 | 0.88 | ITGB1 (0.40) | ACEMMEACE2ITGB1ITGA4 | |
| SCHEMBL5963219 | 0.80 | ACE (0.42) | ACEMMEACE2CPA1MMP1 | |
| SCHEMBL5963440 | 0.80 | ACE (0.42) | ACEMMEACE2CPA1MMP1 | |
| SCHEMBL5963129 | 0.80 | TACR2 (0.50) | ACEMMEACE2CPA1ITGB1 | |
| SCHEMBL3362555 | 0.80 | PPARA (0.46) | ACEMMEACE2CPA1MMP9 | |
| SCHEMBL5963437 | 0.78 | ALDH1A1 (0.38) | MMP1MMP3MMP9 | |
| SCHEMBL16227804 | 0.77 | PSMB8 (0.52) | — | |
| SCHEMBL16227803 | 0.77 | PSMB8 (0.52) | — | |
| SCHEMBL5963752 | 0.76 | ACE (0.60) | ACE | |
| SCHEMBL7306740 | 0.74 | FPR2 (0.59) | ACEMMEACE2KMT2AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | claimed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | claimed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | claimed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | claimed |
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| EP-1540347-A4 | DETECTING RECEPTOR OLIGOMERIZATION | ACLARA BIOSCIENCES INC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | FINK CYNTHIA A | 2006-08-31 | — | — | US | disclosed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | disclosed |
| EP-1540347-A2 | DETECTING RECEPTOR OLIGOMERIZATION | Aclara BioSciences, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004011900-A2 | DETECTING RECEPTOR OLIGOMERIZATION | ACLARA BIOSCIENCES, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | ECE1, ECE2, AGTR1 | ACE 4/4885MME 9/4885ACE2 8/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | ACE 3/4885MME 9/4885ACE2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.